Editorial

Dynamin 2, cell trafficking, and the triple-negative paradox

Dynamin 2, cell trafficking, and the triple-negative paradox

https://doi.org/10.18632/oncotarget.26778 Sophia B. Chernikova, John C. Game,  and J. Martin Brown

2336-2337

PDF  |  How to cite

Activation of RIG-I signaling to increase the pro-inflammatory phenotype of a tumor

Activation of RIG-I signaling to increase the pro-inflammatory phenotype of a tumor

https://doi.org/10.18632/oncotarget.26729 David L. Elion,  and Rebecca S. Cook

2338-2339

PDF  |  How to cite

Research Papers

Co-localization of autophagy-related protein p62 with cancer stem cell marker dclk1 may hamper dclk1’s elimination during colon cancer development and progression

Co-localization of autophagy-related protein p62 with cancer stem cell marker dclk1 may hamper dclk1’s elimination during colon cancer development and progression

https://doi.org/10.18632/oncotarget.26684 Badal Chandra Roy, Ishfaq Ahmed, Satish Ramalingam, Venkatakrishna Jala, Bodduluri Haribabu, Prabhu Ramamoorthy, John Ashcraft, Joseph Valentino, Shrikant Anant, Venkatesh Sampath,  and Shahid Umar

2340-2354

Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite

Novel N,N-dialkyl cyanocinnamic acids as monocarboxylate transporter 1 and 4 inhibitors

Novel N,N-dialkyl cyanocinnamic acids as monocarboxylate transporter 1 and 4 inhibitors

https://doi.org/10.18632/oncotarget.26760 Shirisha Jonnalagadda, Sravan K. Jonnalagadda, Conor T. Ronayne, Grady L. Nelson, Lucas N. Solano, Jon Rumbley, Jon Holy, Venkatram R. Mereddy,  and Lester R. Drewes

2355-2368

Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite

Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma

Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma

https://doi.org/10.18632/oncotarget.26792 Chuang Sun, Aruna Mahendravada, Brandon Ballard, Brandon Kale, Carlos Ramos, John West, Todd Maguire, Katie McKay, Eben Lichtman, Sascha Tuchman, Gianpietro Dotti,  and Barbara Savoldo

2369-2383

Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite

Clinical validation of the tempus xT next-generation targeted oncology sequencing assay

Clinical validation of the tempus xT next-generation targeted oncology sequencing assay

https://doi.org/10.18632/oncotarget.26797 Nike Beaubier, Robert Tell, Denise Lau, Jerod R. Parsons, Stephen Bush, Jason Perera, Shelly Sorrells, Timothy Baker, Alan Chang, Jackson Michuda, Catherine Iguartua, Shelley MacNeil, Kaanan Shah, Philip Ellis, Kimberly Yeatts, Brett Mahon, Timothy Taxter, Martin Bontrager, Aly Khan, Robert Huether, Eric Lefkofsky,  and Kevin P. White

2384-2396

Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite

The combined efficacy of OTS964 and temozolomide for reducing the size of power-law coded heterogeneous glioma stem cell populations

The combined efficacy of OTS964 and temozolomide for reducing the size of power-law coded heterogeneous glioma stem cell populations

https://doi.org/10.18632/oncotarget.26800 Michiya Sugimori, Yumiko Hayakawa, Ryoi Tamura,  and Satoshi Kuroda

2397-2415

Abstract  |  PDF  |  Full Text  |  Supplementary Information  |  How to cite

Errata

Erratum: Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio - Increased expression of galectin-1 in tumors with high stromal content

Erratum: Molecular profiling of colorectal tumors stratified by the histological tumor-stroma ratio - Increased expression of galectin-1 in tumors with high stromal content

https://doi.org/10.18632/oncotarget.26820 Tessa P. Sandberg, Jan Oosting, Gabi W. van Pelt, Wilma E. Mesker, Rob A.E.M. Tollenaar,  and Hans Morreau

2416-2416

Erratum  |  PDF  |  How to cite

Copyright © 2025 Impact Journals, LLC
Impact Journals is a registered trademark of Impact Journals, LLC